Caribou Biosciences, Inc. Board of Directors

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Dr. Rachel E. Haurwitz Ph.D.

Dr. Rachel E. Haurwitz Ph.D.

Co-Founder, CEO, President & Director

Ms. Ruhi A. Khan M.B.A.

Ms. Ruhi A. Khan M.B.A.

Chief Business Officer

Mr. Timothy P. Kelly M.B.A.

Mr. Timothy P. Kelly M.B.A.

Chief Technology Officer

Ms. Amy Figueroa C.F.A.

Ms. Amy Figueroa C.F.A.

Vice President of Investor Relations & Corporate Communications

Ms. Barbara G. McClung Esq., J.D.

Ms. Barbara G. McClung Esq., J.D.

Chief Legal Officer & Corporate Secretary

Ms. Reigin Zawadzki

Ms. Reigin Zawadzki

Chief People Officer

Mr. Sriram Ryali M.B.A.

Mr. Sriram Ryali M.B.A.

Chief Financial Officer

Mr. Daniel Poon

Mr. Daniel Poon

Vice President of Operations & Information Technology

Dr. Steven B. Kanner Ph.D.

Dr. Steven B. Kanner Ph.D.

Chief Scientific Officer

Mr. Ryan Fischesser

Mr. Ryan Fischesser

Interim Principal Accounting Officer & Controller

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.